Innate Pharma presents IPH4502 Phase 1 data, plans dose optimization in post-EV urothelial cancer
IPHA•
IPHA•Innate Pharma reported an unconfirmed disease control rate of 68.4% in Phase 1 escalation of IPH4502 for post-enfortumab vedotin urothelial cancer, with stomatitis the only dose-limiting toxicity. It plans to dose the first patient in dose optimization in H1 2027 and expects its cash runway to last through Q1 2028.
Innate Pharma plans to dose the first patient in IPH4502 Phase 1 dose optimization for post-enfortumab vedotin urothelial cancer in H1 2027. Phase 1 escalation showed an unconfirmed disease control rate of 68.4% in this patient group, with stomatitis the only dose-limiting toxicity.
The TELLOMAK-3 Phase 3 trial of lacutamab has started, with first dosing planned for Q1 2027 and an accelerated approval filing targeted for H2. High-level data from the PACIFIC-9 Phase 3 trial of monalizumab are expected in H1 2027. Innate Pharma expects its cash runway to extend through the end of Q1 2028.